PEGS_Banner_Immunogenicity-Prediction


Innovators in the field of immunogenicity are constantly furthering our understanding of factors that contribute to immunogenicity and developing new and advanced approaches for predicting immunogenicity, for reducing immunogenicity, and for tolerance induction. Presentations at Immunogenicity Prediction and Mitigation will enable attendees to make informed decisions on candidate selection, dosing and formulation, with a view to producing safe and efficacious products in the clinic and beyond.


SUB-VISIBLE PARTICLES, AGGREGATES AND IMMUNOGENICITY

KEYNOTE PRESENTATION: Impact of New Regulations from the USP on Particle Monitoring Approaches

Jack Ragheb, Ph.D., Principal Investigator, Laboratory of Immunology, Division of Therapeutic Proteins, CDER/FDA

Impact of Different Types of Aggregate on Immunogenicity

Narendra Chirmule, Ph.D., Independent Consultant


TOOLS AND APPROACHES FOR IMMUNOGENICITY RISK PREDICTION

Case Studies on Immunogenicity Prediction Strategies for Early Decision-Making in Development

Tim Hickling, Ph.D., Associate Research Fellow, Pharmacokinetics, Dynamics and Metabolism, Pfizer, Inc.

Predictive Studies with Factors VII and VIII based on Genetic Analyses of Patients

Zuben E. Sauna, Ph.D., Principal Investigator, Department of Hematology Research and Review, CDER/FDA

A Systems Pharmacology Approach to Immunogenicity – A Multi-Scale, Mechanistic Mathematical Model and Its Applications

Xiaoying Chen, Ph.D., Principal Scientist, Pharmacokinetics, Dynamics, and Metabolism (PDM), Pfizer, Inc.

Immunogenicity-Driven Late-Onset Hypersensitivity and Ways to Mitigate the Risk

Harald Kropshofer, Ph.D., Director, Senior Personalized Healthcare Leader, Pharmaceutical Development, F. Hoffmann-La Roche Ltd.

Studies on Overcoming Immunogenicity to MAB Products Using Transgenic Mice

Zehra Kaymakcalan, Senior Principal Scientist, Abbvie, Inc.

Development of Humanized Mouse Models for the Study of Immunogenicity

Michael Brehm, Ph.D., Professor, Molecular Medicine, University of Massachusetts


IMMUNOSUPPRESSIVE MECHANISMS AND DEIMMUNIZATION

Case Studies on in silico Predictive Investigations and Deimmunization Using Simple Mouse Models

Ronit Mazor, Ph.D., Postdoctoral Research Fellow, Molecular Biology, National Cancer Institute, NIH

Antibody-Directed Enzyme Pro-Drug Therapy (ADERT ) with De-Immunized Beta Lactamase Protein and with a Lysostaphin that Targets S. Aureus

Karl E. Griswold, Associate Professor, Thayer School of Engineering & Department of Biological Sciences, Dartmouth


NEW APPROACHES TO TOLERANCE INDUCTION

Case Study on Presentation of Antigen in a Tolerogenic Context

Kei Kishimoto, Ph.D., CSO, Selecta Biosciences

Induction of Immunological Tolerance to E. Coli Asparaginase by Engineering Erythrocyte Binding

Stephan Kontos, Ph.D., Co-Founder & Director, Research, Anokion SA



For more details on the conference, please contact:
Nicole Lyscom, Ph.D.
Conference Director
Cambridge Healthtech Institute
T: +44 7791 866489
E: nlyscom@healthtech.com 

For partnering and sponsorship information, please contact:
Jason Gerardi (Companies A-K)
Manager, Business Development
Cambridge Healthtech Institute
T: 781-972-5452
E: jgerardi@healthtech.com 

Carol Dinerstein (Companies L-Z)
Director, Business Development
Cambridge Healthtech Institute
T: 781.972.5471
E: dinerstein@healthtech.com